Cargando…

Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells

BACKGROUND: Arsenic is a widely distributed metalloid compound that has biphasic effects on cultured cells. In large doses, arsenic can be toxic enough to trigger cell death. In smaller amounts, non-toxic doses may promote cell proliferation and induces carcinogenesis. Aberration of chromosome is fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kao, Yu-Ting, Wu, Chin-Han, Wu, Shan-Ying, Lan, Sheng-Hui, Liu, Hsiao-Sheng, Tseng, Ya-Shih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394624/
https://www.ncbi.nlm.nih.gov/pubmed/28420331
http://dx.doi.org/10.1186/s12885-017-3253-1
_version_ 1783229755737243648
author Kao, Yu-Ting
Wu, Chin-Han
Wu, Shan-Ying
Lan, Sheng-Hui
Liu, Hsiao-Sheng
Tseng, Ya-Shih
author_facet Kao, Yu-Ting
Wu, Chin-Han
Wu, Shan-Ying
Lan, Sheng-Hui
Liu, Hsiao-Sheng
Tseng, Ya-Shih
author_sort Kao, Yu-Ting
collection PubMed
description BACKGROUND: Arsenic is a widely distributed metalloid compound that has biphasic effects on cultured cells. In large doses, arsenic can be toxic enough to trigger cell death. In smaller amounts, non-toxic doses may promote cell proliferation and induces carcinogenesis. Aberration of chromosome is frequently detected in epithelial cells and lymphocytes of individuals from arsenic contaminated areas. Overexpression of Aurora-A, a mitotic kinase, results in chromosomal instability and cell transformation. We have reported that low concentration (≦1 μM) of arsenic treatment increases Aurora-A expression in immortalized bladder urothelial E7 cells. However, how arsenic induces carcinogenesis through Aurora-A activation remaining unclear. METHODS: Bromodeoxyuridine (BrdU) staining, MTT assay, and flow cytometry assay were conducted to determine cell proliferation. Messenger RNA and protein expression levels of Aurora-A were detected by reverse transcriptional-PCR and Western blotting, respectively. Centrosome of cells was observed by immunofluorescent staining. The transcription factor of Aurora-A was investigated by promoter activity, chromosome immunoprecipitation (ChIP), and small interfering RNA (shRNA) assays. Mouse model was utilized to confirm the relationship between arsenic and Aurora-A. RESULTS: We reveal that low dosage of arsenic treatment increased cell proliferation is associated with accumulated cell population at S phase. We also detected increased Aurora-A expression at mRNA and protein levels in immortalized bladder urothelial E7 cells exposed to low doses of arsenic. Arsenic-treated cells displayed increased multiple centrosome which is resulted from overexpressed Aurora-A. Furthermore, the transcription factor, E2F1, is responsible for Aurora-A overexpression after arsenic treatment. We further disclosed that Aurora-A expression and cell proliferation were increased in bladder and uterus tissues of the BALB/c mice after long-term arsenic (1 mg/L) exposure for 2 months. CONCLUSION: We reveal that low dose of arsenic induced cell proliferation is through Aurora-A overexpression, which is transcriptionally regulated by E2F1 both in vitro and in vivo. Our findings disclose a new possibility that arsenic at low concentration activates Aurora-A to induce carcinogenesis.
format Online
Article
Text
id pubmed-5394624
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53946242017-04-20 Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells Kao, Yu-Ting Wu, Chin-Han Wu, Shan-Ying Lan, Sheng-Hui Liu, Hsiao-Sheng Tseng, Ya-Shih BMC Cancer Research Article BACKGROUND: Arsenic is a widely distributed metalloid compound that has biphasic effects on cultured cells. In large doses, arsenic can be toxic enough to trigger cell death. In smaller amounts, non-toxic doses may promote cell proliferation and induces carcinogenesis. Aberration of chromosome is frequently detected in epithelial cells and lymphocytes of individuals from arsenic contaminated areas. Overexpression of Aurora-A, a mitotic kinase, results in chromosomal instability and cell transformation. We have reported that low concentration (≦1 μM) of arsenic treatment increases Aurora-A expression in immortalized bladder urothelial E7 cells. However, how arsenic induces carcinogenesis through Aurora-A activation remaining unclear. METHODS: Bromodeoxyuridine (BrdU) staining, MTT assay, and flow cytometry assay were conducted to determine cell proliferation. Messenger RNA and protein expression levels of Aurora-A were detected by reverse transcriptional-PCR and Western blotting, respectively. Centrosome of cells was observed by immunofluorescent staining. The transcription factor of Aurora-A was investigated by promoter activity, chromosome immunoprecipitation (ChIP), and small interfering RNA (shRNA) assays. Mouse model was utilized to confirm the relationship between arsenic and Aurora-A. RESULTS: We reveal that low dosage of arsenic treatment increased cell proliferation is associated with accumulated cell population at S phase. We also detected increased Aurora-A expression at mRNA and protein levels in immortalized bladder urothelial E7 cells exposed to low doses of arsenic. Arsenic-treated cells displayed increased multiple centrosome which is resulted from overexpressed Aurora-A. Furthermore, the transcription factor, E2F1, is responsible for Aurora-A overexpression after arsenic treatment. We further disclosed that Aurora-A expression and cell proliferation were increased in bladder and uterus tissues of the BALB/c mice after long-term arsenic (1 mg/L) exposure for 2 months. CONCLUSION: We reveal that low dose of arsenic induced cell proliferation is through Aurora-A overexpression, which is transcriptionally regulated by E2F1 both in vitro and in vivo. Our findings disclose a new possibility that arsenic at low concentration activates Aurora-A to induce carcinogenesis. BioMed Central 2017-04-18 /pmc/articles/PMC5394624/ /pubmed/28420331 http://dx.doi.org/10.1186/s12885-017-3253-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kao, Yu-Ting
Wu, Chin-Han
Wu, Shan-Ying
Lan, Sheng-Hui
Liu, Hsiao-Sheng
Tseng, Ya-Shih
Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells
title Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells
title_full Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells
title_fullStr Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells
title_full_unstemmed Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells
title_short Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells
title_sort arsenic treatment increase aurora-a overexpression through e2f1 activation in bladder cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394624/
https://www.ncbi.nlm.nih.gov/pubmed/28420331
http://dx.doi.org/10.1186/s12885-017-3253-1
work_keys_str_mv AT kaoyuting arsenictreatmentincreaseauroraaoverexpressionthroughe2f1activationinbladdercells
AT wuchinhan arsenictreatmentincreaseauroraaoverexpressionthroughe2f1activationinbladdercells
AT wushanying arsenictreatmentincreaseauroraaoverexpressionthroughe2f1activationinbladdercells
AT lanshenghui arsenictreatmentincreaseauroraaoverexpressionthroughe2f1activationinbladdercells
AT liuhsiaosheng arsenictreatmentincreaseauroraaoverexpressionthroughe2f1activationinbladdercells
AT tsengyashih arsenictreatmentincreaseauroraaoverexpressionthroughe2f1activationinbladdercells